Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments.
Twenty-one premenopausal patients with metastatic breast cancer (unselected for receptor status) were treated during 3-14 months with the potent LHRH-agonist Buserelin (Hoe 766) as a first-line therapy. In one-third of 12 patients treated with Buserelin alone an objective tumour response was observed in the absence of side effects. The longest duration of response occurred in 2 patients with complete remissions (14+ and 13+ months). After addition and in combination with tamoxifen this LHRH-agonist treatment caused an objective response in about half (8/17) of the patients. A problem appears to be the great variation in hormonal response especially during the combination treatment with tamoxifen, which was not found during combination treatment with megestrol acetate in 4 patients. Ultimately, of the whole group of 21 patients, 9 patients (43%) showed an objective remission, 6 stable disease and 6 progression of tumour growth.
D001943:Breast Neoplasms / Q000188:drug therapy*; D002064:Buserelin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008535:Megestrol / Q000008:administration & dosage / Q000031:analogs & derivatives; D019290:Megestrol Acetate; D013629:Tamoxifen / Q000008:administration & dosage
D013629:Tamoxifen; D008535:Megestrol; D002064:Buserelin; D019290:Megestrol Acetate